Caption Management’s Immunocore IMCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$37.5M Buy
1,242,500
+1,217,500
+4,870% +$39.4M 0.22% 95
2025
Q4
$868K Sell
25,000
-1,527,500
-98% -$53.9M 0.01% 1107
2025
Q3
$56.4M Buy
1,552,500
+865,300
+126% +$29.4M 0.44% 35
2025
Q2
$21.6M Buy
687,200
+659,700
+2,399% +$20.5M 0.24% 85
2025
Q1
$816K Buy
+27,500
New +$825K 0.01% 975
2024
Q4
Sell
-12,500
Closed -$389K 1625
2024
Q3
$389K Buy
+12,500
New +$455K 0.01% 972
2024
Q2
Sell
-37,600
Closed -$2.44M 1323
2024
Q1
$2.44M Buy
+37,600
New +$2.58M 0.04% 478
2023
Q1
Sell
-27,500
Closed -$1.57M 1289
2022
Q4
$1.57M Buy
+27,500
New +$1.55M 0.02% 620

Other funds holding IMCR

Caption Management's IMCR Position: Q1 2026 in Review

Caption Management increased its Immunocore (IMCR) stake by 601% in Q1 2026, buying an estimated $18.4M and bringing the position to 661,786 shares worth $20M. The position accounts for 0.12% of the portfolio, ranked #188.

Caption Management first reported a position in IMCR in Q4 2022 and has held it in 7 quarters since. 142 funds tracked by Wall St. Rank hold IMCR as of Q1 2026.

  • Caption Management held 661,786 shares of Immunocore worth $20M as of Q1 2026.
  • Caption Management bought 567,402 Immunocore shares in Q1 2026, an estimated $18.4M.
  • Immunocore made up 0.12% of Caption Management's portfolio in Q1 2026, its #188 holding.
  • Caption Management first reported a position in Immunocore in Q4 2022 and has held it in 7 quarters since.
  • 142 funds tracked by Wall St. Rank held Immunocore as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.